IL-17 Inhibitors and the Risk of Malignancy. Canadian Dermatology Today, Toronto, Canada, v. 3, n. 1, p. 18–21, 2022. Disponível em: https://canadiandermatologytoday.com/article/view/3-1-mak. Acesso em: 17 sep. 2026.